ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Protein Language Model-Guided Engineering of a 2,3-Butanediol Dehydrogenase for the Enantioselective Synthesis of Cyclic α-Hydroxy Ketones.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
(2R,3R)-butanediol dehydrogenases (BDHs) are promising catalysts for the production of α-hydroxy ketones, which are highly valuable compounds in the synthesis of fine chemicals and pharmaceuticals. However, (2R,3R)-BDHs display limited stereoselectivity, thus restricting wider applications. In this study, we engineered a (2R,3R)-BDH from Bacillus subtilis (BsBDH) to enhance and invert its stereoselectivity toward 1,2-cyclohexanediol (1,2-CHD) for the production of chiral 2-hydroxycyclohexanone. The hot spots 115, 118, 293 of BsBDH were initially identified using the protein language model ESM-1v. Subsequently, to obtain a stable scaffold to engineer stereoselectivity, we devised a strategy of position analysis and source search, achieving a true-positive rate of 88.2% in designing thermostable single variants. Furthermore, iterative saturation mutagenesis was applied to the hot spots of the thermostable variant 6M2, and obtained a trans-CHD preference variant LTF (ee > 99%) and a cis-CHD preference variant 10M (ee > 99%). Several high-activity variants were also obtained, including 6M2/F115C/L118F and 6M2/F115L/L118M, which demonstrated the activity improvements toward 25 substrates, with the highest enhancement reaching 5183.1-fold. Additionally, molecular dynamics (MD) simulations and the incorporation of non-canonical amino acids (ncAAs) were utilized to elucidate the mechanisms underlying the variants. The engineered BsBDH variants exhibit promising potential for the biocatalytic production of α-hydroxyketones.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.